Mobia Medical, Inc. IPO - What You Need to Know

Thinking about the Mobia Medical IPO? It’s exciting to get in early, but let’s break down the details in plain English before you invest.

1. What does this company do?

Mobia Medical helps stroke survivors regain movement. Their main product, the Vivistim System, is an FDA-approved device for people with arm and hand weakness. It uses Vagus Nerve Stimulation (VNS) therapy. During physical therapy, the device sends tiny pulses to the vagus nerve, which helps the brain "rewire" itself to improve motor skills.

Patients see benefits even years after a stroke. The device requires a one-hour surgery to implant, followed by rehabilitation. Patient satisfaction is high, and many specialized stroke centers are adopting the technology.

2. The IPO Details

Mobia is joining the Nasdaq under the ticker "MOBI."

• The Price: They plan to sell 10 million shares at roughly $15.00 each.
• The Goal: They aim to raise about $134.5 million. They will use this cash to hire more salespeople, fund new research, and cover daily business costs.
• Big Changes: The company is simplifying its ownership structure before the IPO. They are converting preferred stock and debt into common stock. This means more shares will be issued, which reduces your ownership percentage compared to what it would have been otherwise.

3. How is the business doing?

Mobia is growing, but they are spending cash quickly to scale.

• The Growth: Revenue hit $32 million in 2025, up from $15.6 million in 2024. More doctors are training to use the device, and more hospitals are offering the procedure.
• The Losses: Despite this growth, the company is not yet profitable. They lost $46.5 million in 2025. Most of this money goes toward their specialized sales team and clinical trials.
• The "Going Concern" Warning: Auditors have issued a "going concern" warning. This means there is doubt about the company’s ability to stay in business over the next year without the cash from this IPO. This offering is essential for their survival.

4. What are the main risks?

Investing in an IPO is risky. Keep these points in mind:

• Financial Health: Because they lose money, they could run out of cash. If they don't reach profitability or raise more money later, the company may fail.
• Single-Product Risk: Their entire business depends on the Vivistim System. If insurance companies stop paying for the procedure, or if a competitor creates a better product, Mobia has no other products to fall back on.
• High Expenses: Being a public company is expensive. New costs for legal compliance and financial reporting will put more pressure on their bottom line and could delay their path to profit.

Final Thoughts for Investors

Before you decide to buy, ask yourself if you are comfortable with the "all-in" nature of this company. They are betting everything on one technology. While the growth in revenue is promising, the "going concern" warning is a serious signal that this is a high-stakes investment.

IPOs are often volatile, with prices swinging wildly in the first few weeks. Don’t feel pressured to buy the moment the market opens. Take your time to watch how the stock performs and consider whether this fits your personal risk tolerance.

Disclaimer: I am an AI, not a financial advisor. This guide is for educational purposes only. Always do your own research or talk to a professional before investing.